肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Oncologist 等：肥胖类型对乳腺癌风险影响因HR状态而异/ NSM可有效降低BRCA突变人群乳腺癌风险/根据患者年龄及肿瘤分子分型预测腋窝手术强度

2017-09-24 佚名 肿瘤资讯

肥胖类型乳腺癌风险NSMBRCA突变
关注

肥胖类型对乳腺癌风险影响因HR状态而异/ NSM可有效降低BRCA突变人群乳腺癌风险/根据患者年龄及肿瘤分子分型预测腋窝手术强度

【The Oncologist】中国多中心研究：肥胖类型对乳腺癌风险的影响因HR状态而异

来自中国东北地区多中心大样本病例对照研究入组1439例年龄25-70岁确诊乳腺癌的汉族女性，对照组为门诊定期体检的健康人群，两组年龄、随访时间相仿。结果提示BMI、腰臀比与乳腺癌总风险成正比；BMI与ER+PR+乳腺癌风险、绝经前女性乳腺癌风险成正比；腰臀比与HR-乳腺癌风险成正比、与绝经前女性HR+乳腺癌风险成反比；腰臀比>0.85与绝经后女性HR-乳腺癌风险增加有相关。反映全身型肥胖的BMI与ER+PR+乳腺癌风险相关性更强，尤其绝经前女性；反映向心型肥胖的腰臀比，对HR-乳腺癌风险更有特异性，尤其绝经后女性。上述结果表明，不同类型肥胖可能对不同的乳腺癌亚型发挥不同的作用，对于不同肥胖类型女性，可能需要不同的化学预防策略。

【JAMA Surg】保留乳头的全乳切除术（NSM）可有效降低BRCA突变人群乳腺癌风险

该多中心回顾性研究纳入了为了减少风险而接受对侧乳房切除术的乳腺癌患者，主要结局指标为预防性NSM后出现新的乳腺癌。中位随访34个月，分别有58.4%及41.6%接受了双侧或单侧预防性 NSM；BRCA1或BRCA2突变患者分别为201例及145例；所有预防性NSM后未发生同侧乳腺癌，双侧预防性NSM后未发生任何乳腺癌；用BRCA1/2突变携带者风险模型推算，如果不接受预防性NSM可有大约22例新的原发性乳腺癌；预防性NSM可使乳腺癌事件显着减少。

【Ann Surg Oncol】根据患者年龄及肿瘤分子分型预测腋窝手术强度
该研究根据患者年龄和肿瘤亚型，对符合Z0011研究标准的女性腋窝手术强度进行了调查。该研究通过国家癌症数据库找出2009～2014年诊断为cT1-2cN0乳腺癌，且1～2个阳性淋巴结转移并采用肿块切除术治疗的患者。SLNB被定义为清除1～5个淋巴结，ALND被定义为清除≥10个淋巴结。结果发现，单纯SLNB与SLNB＋ALND相比：年龄≥70岁患者比例较高，术后进行放疗的比例相似。年轻患者（<40岁vs.≥70岁）、HER2+及三阴性乳腺癌患者（vs.luminal型）进行单纯前哨淋巴结活检的比例较低。

原始出处：
[1]Wang F, Liu L, Cui S, et al.Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status： Results from a Case-Control Study in Northern and Eastern China and Implications for Chemoprevention.Oncologist. 2017 Sep 14. [Epub ahead of print]
[2]James W.Jakub,MD; Anne WarrenPeled,MD; Richard J.Gray,MD.et al.Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations： A Multi-institutional Study.JAMA Surg. 2017 Sep 13. [Epub ahead of print]
[3]CeciliaT.OngSamanthaM.ThomasRachelC.Blitzblau.et al.Patient Age and Tumor Subtype Predict the Extent of Axillary Surgery Among Breast Cancer Patients Eligible for the American College of Surgeons Oncology Group Trial Z0011.Ann Surg Oncol. 2017 Sep 6. [Epub ahead of print]

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2078078, encodeId=110320e807881, content=<a href='/topic/show?id=eadf82828a1' target=_blank style='color:#2F92EE;'>#肿瘤分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82828, encryptionId=eadf82828a1, topicName=肿瘤分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat May 26 21:48:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770283, encodeId=1dc01e702836c, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sun Feb 25 20:48:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810520, encodeId=ee4218105201c, content=<a href='/topic/show?id=aee48532109' target=_blank style='color:#2F92EE;'>#腋窝手术强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85321, encryptionId=aee48532109, topicName=腋窝手术强度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=649f191, createdName=zzc2211, createdTime=Sat Apr 28 06:48:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865126, encodeId=c68c186512604, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Apr 01 12:48:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061671, encodeId=05cc20616e1b2, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Mar 24 12:48:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418338, encodeId=067c14183385b, content=<a href='/topic/show?id=39fd3e036a' target=_blank style='color:#2F92EE;'>#BRCA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3703, encryptionId=39fd3e036a, topicName=BRCA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=793f3344126, createdName=zhanglin3080, createdTime=Tue Sep 26 11:48:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455140, encodeId=8059145514058, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Tue Sep 26 11:48:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594019, encodeId=0d0215940198e, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 26 11:48:00 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2018-05-26 howi

    #肿瘤分子#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2078078, encodeId=110320e807881, content=<a href='/topic/show?id=eadf82828a1' target=_blank style='color:#2F92EE;'>#肿瘤分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82828, encryptionId=eadf82828a1, topicName=肿瘤分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat May 26 21:48:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770283, encodeId=1dc01e702836c, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sun Feb 25 20:48:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810520, encodeId=ee4218105201c, content=<a href='/topic/show?id=aee48532109' target=_blank style='color:#2F92EE;'>#腋窝手术强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85321, encryptionId=aee48532109, topicName=腋窝手术强度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=649f191, createdName=zzc2211, createdTime=Sat Apr 28 06:48:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865126, encodeId=c68c186512604, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Apr 01 12:48:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061671, encodeId=05cc20616e1b2, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Mar 24 12:48:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418338, encodeId=067c14183385b, content=<a href='/topic/show?id=39fd3e036a' target=_blank style='color:#2F92EE;'>#BRCA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3703, encryptionId=39fd3e036a, topicName=BRCA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=793f3344126, createdName=zhanglin3080, createdTime=Tue Sep 26 11:48:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455140, encodeId=8059145514058, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Tue Sep 26 11:48:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594019, encodeId=0d0215940198e, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 26 11:48:00 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2018-02-25 gaoxiaoe

    #乳腺癌风险#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2078078, encodeId=110320e807881, content=<a href='/topic/show?id=eadf82828a1' target=_blank style='color:#2F92EE;'>#肿瘤分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82828, encryptionId=eadf82828a1, topicName=肿瘤分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat May 26 21:48:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770283, encodeId=1dc01e702836c, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sun Feb 25 20:48:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810520, encodeId=ee4218105201c, content=<a href='/topic/show?id=aee48532109' target=_blank style='color:#2F92EE;'>#腋窝手术强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85321, encryptionId=aee48532109, topicName=腋窝手术强度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=649f191, createdName=zzc2211, createdTime=Sat Apr 28 06:48:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865126, encodeId=c68c186512604, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Apr 01 12:48:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061671, encodeId=05cc20616e1b2, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Mar 24 12:48:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418338, encodeId=067c14183385b, content=<a href='/topic/show?id=39fd3e036a' target=_blank style='color:#2F92EE;'>#BRCA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3703, encryptionId=39fd3e036a, topicName=BRCA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=793f3344126, createdName=zhanglin3080, createdTime=Tue Sep 26 11:48:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455140, encodeId=8059145514058, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Tue Sep 26 11:48:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594019, encodeId=0d0215940198e, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 26 11:48:00 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2018-04-28 zzc2211

    #腋窝手术强度#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2078078, encodeId=110320e807881, content=<a href='/topic/show?id=eadf82828a1' target=_blank style='color:#2F92EE;'>#肿瘤分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82828, encryptionId=eadf82828a1, topicName=肿瘤分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat May 26 21:48:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770283, encodeId=1dc01e702836c, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sun Feb 25 20:48:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810520, encodeId=ee4218105201c, content=<a href='/topic/show?id=aee48532109' target=_blank style='color:#2F92EE;'>#腋窝手术强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85321, encryptionId=aee48532109, topicName=腋窝手术强度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=649f191, createdName=zzc2211, createdTime=Sat Apr 28 06:48:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865126, encodeId=c68c186512604, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Apr 01 12:48:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061671, encodeId=05cc20616e1b2, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Mar 24 12:48:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418338, encodeId=067c14183385b, content=<a href='/topic/show?id=39fd3e036a' target=_blank style='color:#2F92EE;'>#BRCA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3703, encryptionId=39fd3e036a, topicName=BRCA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=793f3344126, createdName=zhanglin3080, createdTime=Tue Sep 26 11:48:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455140, encodeId=8059145514058, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Tue Sep 26 11:48:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594019, encodeId=0d0215940198e, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 26 11:48:00 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2018-04-01 minlingfeng

    #Oncol#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2078078, encodeId=110320e807881, content=<a href='/topic/show?id=eadf82828a1' target=_blank style='color:#2F92EE;'>#肿瘤分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82828, encryptionId=eadf82828a1, topicName=肿瘤分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat May 26 21:48:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770283, encodeId=1dc01e702836c, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sun Feb 25 20:48:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810520, encodeId=ee4218105201c, content=<a href='/topic/show?id=aee48532109' target=_blank style='color:#2F92EE;'>#腋窝手术强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85321, encryptionId=aee48532109, topicName=腋窝手术强度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=649f191, createdName=zzc2211, createdTime=Sat Apr 28 06:48:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865126, encodeId=c68c186512604, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Apr 01 12:48:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061671, encodeId=05cc20616e1b2, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Mar 24 12:48:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418338, encodeId=067c14183385b, content=<a href='/topic/show?id=39fd3e036a' target=_blank style='color:#2F92EE;'>#BRCA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3703, encryptionId=39fd3e036a, topicName=BRCA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=793f3344126, createdName=zhanglin3080, createdTime=Tue Sep 26 11:48:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455140, encodeId=8059145514058, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Tue Sep 26 11:48:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594019, encodeId=0d0215940198e, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 26 11:48:00 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2018-03-24 sjq027

    #癌风险#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2078078, encodeId=110320e807881, content=<a href='/topic/show?id=eadf82828a1' target=_blank style='color:#2F92EE;'>#肿瘤分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82828, encryptionId=eadf82828a1, topicName=肿瘤分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat May 26 21:48:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770283, encodeId=1dc01e702836c, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sun Feb 25 20:48:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810520, encodeId=ee4218105201c, content=<a href='/topic/show?id=aee48532109' target=_blank style='color:#2F92EE;'>#腋窝手术强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85321, encryptionId=aee48532109, topicName=腋窝手术强度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=649f191, createdName=zzc2211, createdTime=Sat Apr 28 06:48:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865126, encodeId=c68c186512604, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Apr 01 12:48:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061671, encodeId=05cc20616e1b2, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Mar 24 12:48:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418338, encodeId=067c14183385b, content=<a href='/topic/show?id=39fd3e036a' target=_blank style='color:#2F92EE;'>#BRCA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3703, encryptionId=39fd3e036a, topicName=BRCA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=793f3344126, createdName=zhanglin3080, createdTime=Tue Sep 26 11:48:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455140, encodeId=8059145514058, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Tue Sep 26 11:48:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594019, encodeId=0d0215940198e, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 26 11:48:00 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2017-09-26 zhanglin3080

    #BRCA突变#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2078078, encodeId=110320e807881, content=<a href='/topic/show?id=eadf82828a1' target=_blank style='color:#2F92EE;'>#肿瘤分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82828, encryptionId=eadf82828a1, topicName=肿瘤分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat May 26 21:48:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770283, encodeId=1dc01e702836c, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sun Feb 25 20:48:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810520, encodeId=ee4218105201c, content=<a href='/topic/show?id=aee48532109' target=_blank style='color:#2F92EE;'>#腋窝手术强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85321, encryptionId=aee48532109, topicName=腋窝手术强度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=649f191, createdName=zzc2211, createdTime=Sat Apr 28 06:48:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865126, encodeId=c68c186512604, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Apr 01 12:48:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061671, encodeId=05cc20616e1b2, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Mar 24 12:48:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418338, encodeId=067c14183385b, content=<a href='/topic/show?id=39fd3e036a' target=_blank style='color:#2F92EE;'>#BRCA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3703, encryptionId=39fd3e036a, topicName=BRCA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=793f3344126, createdName=zhanglin3080, createdTime=Tue Sep 26 11:48:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455140, encodeId=8059145514058, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Tue Sep 26 11:48:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594019, encodeId=0d0215940198e, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 26 11:48:00 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2017-09-26 july_977

    #GIST#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2078078, encodeId=110320e807881, content=<a href='/topic/show?id=eadf82828a1' target=_blank style='color:#2F92EE;'>#肿瘤分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82828, encryptionId=eadf82828a1, topicName=肿瘤分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat May 26 21:48:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770283, encodeId=1dc01e702836c, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sun Feb 25 20:48:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810520, encodeId=ee4218105201c, content=<a href='/topic/show?id=aee48532109' target=_blank style='color:#2F92EE;'>#腋窝手术强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85321, encryptionId=aee48532109, topicName=腋窝手术强度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=649f191, createdName=zzc2211, createdTime=Sat Apr 28 06:48:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865126, encodeId=c68c186512604, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Apr 01 12:48:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061671, encodeId=05cc20616e1b2, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Mar 24 12:48:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418338, encodeId=067c14183385b, content=<a href='/topic/show?id=39fd3e036a' target=_blank style='color:#2F92EE;'>#BRCA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3703, encryptionId=39fd3e036a, topicName=BRCA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=793f3344126, createdName=zhanglin3080, createdTime=Tue Sep 26 11:48:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455140, encodeId=8059145514058, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Tue Sep 26 11:48:00 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594019, encodeId=0d0215940198e, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 26 11:48:00 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2017-09-26 智智灵药

    #BRCA#

    0